Screening Questionnaires and Musculoskeletal Ultrasound for Early Detection of Spondyloarthritis in IBD Patients (IBD-MSUS)

July 19, 2026 updated by: Shaimaa Salah Abdelaziz Sayed, Assiut University

Incremental Value of Musculoskeletal Ultrasound After DETAIL and IBIS-Q Screening for Early Detection of IBD-associated Spondyloarthritis.

This study aims to evaluate the screening performance of the DETAIL and IBIS-Q questionnaires followed by musculoskeletal ultrasound (MSUS) for the early detection of spondyloarthritis in patients previously diagnosed with Inflammatory Bowel Disease (IBD).

Study Overview

Status

Not yet recruiting

Detailed Description

Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations, with spondyloarthritis (SpA) being the most common. Early detection is crucial to prevent structural damage. This prospective study will screen consecutive adult patients with IBD using the DETAIL and IBIS-Q questionnaires. Patients will then undergo a comprehensive clinical and musculoskeletal ultrasound (MSUS) assessment to evaluate the incremental diagnostic value of ultrasound in detecting early and subclinical SpA.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Asyut Governorate
      • Asyut, Asyut Governorate, Egypt, 71515

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients with inflammatory bowel disease (IBD) attending the gastroenterology and outpatient clinics at Assiut University Hospital, who will be sequentially screened for early detection of associated spondyloarthritis.

Description

Inclusion Criteria:

Adult Aged 18 years old or more Confirmed diagnosis of IBD (by established clinical, endoscopic, and histopathological criteria).

Patient provides informed written consent to participate

Exclusion Criteria:

Known, pre-existing diagnosis of Spondyloarthritis or any other concomitant systemic autoimmune rheumatic disease.

Severe secondary osteoarthritis or major joint trauma/surgery mimicking SpA. Cognitive impairment or communication barriers preventing comprehension or completion of questionnaires

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
IBD Patients
consecutive adult patients diagnosed with Inflammatory Bowel Disease (IBD) who will undergo screening for early detection of spondyloarthritis.
All patients will be screened using the DETAIL and IBIS-Q questionnaires, followed by a comprehensive musculoskeletal ultrasound (MSUS) assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of undiagnosed spondyloarthritis
Time Frame: At the time of clinical evaluation (up to 12 months)
The percentage of patients with inflammatory bowel disease (IBD) who are newly diagnosed with spondyloarthritis based on DETAIL and IBIS-Q questionnaires followed by musculoskeletal ultrasound (MSUS).
At the time of clinical evaluation (up to 12 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

July 19, 2026

First Submitted That Met QC Criteria

July 19, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 19, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

To protect patient privacy and confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spondylarthritis

Clinical Trials on DETAIL .IBIS_Q . MSUS

Subscribe